Winner of the 2021 Catalyst for Precision Medicine Award — Colin Pritchard
For targeted cancer therapies to be effective, they need to be matched with patients who will benefit from them. At the University of Washington and the Brotman Baty Institute, Colin Pritchard is turning next-generation genetic sequencing into a risk assessment and patient-therapy matching tool. In just a few years, Pritchard has adapted the technique to identify patients with genetic cancer risk, including Lynch Syndrome and King Syndrome (also known as HBOC), common but under-diagnosed conditions that can lead to various cancers. Other work by Pritchard and his colleagues helped to develop molecular diagnostics that led to better targeted treatments for cancer patients.
For more remarkable stories from the 2021 Winners of the Cancer Community Awards, visit our Heroes of Cancer Care collection.
